March 16, 2026 a 12:38 pm
EW: Analysts Ratings - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation remains a focal point in the cardiovascular medical devices sector. The company's innovative solutions in transcatheter valve technologies bolster its market position. Analysts generally maintain a positive outlook, reflecting confidence in EW's strategic direction and expansion potential in international markets.
Historical Stock Grades
A detailed assessment of the latest rating data for Edwards Lifesciences Corporation reveals a predominantly positive sentiment among analysts, with no Sell or Strong Sell recommendations. The consensus leans towards "Buy" with a considerable score in the evaluation.
| Rating Category | Number of Ratings | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 16 | |
| Hold | 12 | |
| Sell | 0 | |
| Strong Sell | 0 |
Analyst Ratings History Chart
Stock Performance Chart
Sentiment Development
Over the last several months, the sentiment regarding Edwards Lifesciences has shown stability, particularly in the "Buy" and "Hold" categories.
- The "Buy" ratings have remained consistently high, indicating sustained investor confidence.
- There is a notable stability in "Hold" ratings, reflecting a cautious optimism.
- No "Sell" or "Strong Sell" recommendations indicate a lack of major downside risk perception among analysts.
Percentage Trends
Analyzing percentage shifts reveals a minor reallocation between "Buy" and "Hold" categories, with a slight increase in "Buy" recommendations.
- As of March 2026, "Strong Buy" makes up approximately 17% of total analyst opinions.
- There is a consistent preference for "Buy", which constitutes about 53% of total recommendations.
- "Hold" ratings represent around 30% of the total, reflecting slight caution.
- No shifts towards more negative ratings are observed, underscoring robust market confidence.
Latest Analyst Recommendations
The latest artist recommendations showcase a continuity in maintaining existing outlooks. There are no downgrades, underscoring steady confidence.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-11 | Overweight | Overweight | Wells Fargo |
| 2026-02-11 | Hold | Hold | Truist Securities |
| 2026-02-11 | Buy | Buy | Goldman Sachs |
| 2026-02-11 | Overweight | Overweight | Piper Sandler |
| 2026-02-11 | Buy | Buy | BTIG |
Analyst Recommendations with Change of Opinion
Recent changes in opinion highlight an upward adjustment in ratings for Edwards Lifesciences, indicative of growing optimism for the company's future prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-09 | Buy | Hold | TD Cowen |
| 2025-12-18 | Overweight | Neutral | JP Morgan |
| 2025-10-29 | Peer Perform | Underperform | Wolfe Research |
| 2025-10-29 | Buy | Hold | Jefferies |
| 2025-10-08 | Perform | Outperform | Oppenheimer |
Interpretation
The overall analyst sentiment for Edwards Lifesciences suggests a cautiously optimistic outlook. While the absence of negative ratings underpins a strong belief in the company's prospects, the presence of a significant number of Hold ratings indicates some degree of unpredictability. The observed upgrades highlight a rejuvenation of enthusiasm, suggesting confidence in the company's strategic initiatives and market expansions. However, analysts are likely maintaining vigilance regarding market challenges which could impact future performance.
Conclusion
Edwards Lifesciences Corporation is viewed favorably within its industry, propelled by its innovation and reliable growth strategy. While the majority of ratings endorse the company as a favorable investment, the consistent Hold grades underscore an awareness of potential hurdles. The balanced analyst perspective, leaning towards Buy, presents opportunities for investors, while reiterating the need for strategic observation as the company navigates an evolving medical devices landscape. Overall, the sentiment suggests Edwards Lifesciences holds promise with manageable risks.